BiPar Sciences, Inc. Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs
Published: Sep 10, 2009
SAN FRANCISCO, Sept. 10, 2009 (GLOBE NEWSWIRE) -- Tom White, cofounder and former chief executive officer (CEO) of BiPar Sciences, the successful biotech firm recently acquired by Sanofi-Aventis for $500 million, announced today that G. Kirk Raab and John Schembri have joined TriAct Therapeutics, a clinical-stage biopharmaceutical company developing novel signaling pathway inhibitors to address the significant unmet needs of lung cancer patients. White co-founded TriAct with a group from UCSF, and serves as its president and CEO. Raab and Schembri will serve in the Chairman and Chief Financial Officer (CFO) roles, respectively, at TriAct. The company is also searching for senior clinical and regulatory personnel to fill out its team.